The European Commission (EC) has conditionally approved MSD's Welireg, an oral hypoxia-inducible factor-2 alpha (HIF-2α) ...

Merck & Co has extended its range of cancer medicines in the US after claiming FDA approval for Welireg – a drug it acquired as part of its $2.2 billion takeover of Peloton Therapeutics in 2019 ...

MSD acquired Welireg when it bought Peloton Therapeutics for an upfront payment of $1.05bn in 2019. In August 2021, the drug was first approved by the FDA for the treatment of a rare disorder ...

The FDA has approved MSD’s oral HIF-2 alpha inhibitor Welireg for a second cancer indication, relapsed or refractory advanced renal cell carcinoma (RCC), the most common form of kidney cancer.

Adjusted operating loss is expected to be less than $495 million. EU Approval to Merck’s Welireg for Two Indications The European Commission approved Merck’s Welireg as a monotherapy for ...

Among the recent company’s developments is the European Commission’s conditional approval for Merck & Co.’s WELIREG (belzutifan), the first oral HIF-2α inhibitor in the EU, for two ...

Strategic efforts like the FDA's priority review for KEYTRUDA® and European approval for WELIREG® strengthen its oncology portfolio. Meanwhile, a collaboration with Sierra Space points to ...